

brigatinib tablet (ALUNBRIG)

Diagnosis Considered for Coverage:

- Non-Small Cell Lung Cancer (NSCLC)
- Histiocytic Neoplasms of Erdheim Chester Disease
- Soft Tissue Sarcoma inflammatory myofibroblastic tumor (IMT) with ALK translocation
- Uterine Sarcoma

Coverage Criteria:

For non-small cell lung cancer:

- Presence of the anaplastic lymphoma kinase (ALK) gene rearrangement, **and**
- Being used as single agent, **and**
- Dose does not exceed 180 mg per day.

For histiocytic neoplasms of Erdheim-Chester disease:

- Presence of the anaplastic lymphoma kinase (ALK) gene fusion, **and**
- Being used as single agent.

For soft tissue sarcoma:

- Being used for inflammatory myofibroblastic tumor, **and**
- Presence of the anaplastic lymphoma kinase (ALK) gene rearrangement, **and**
Being used as a single agent.

For uterine sarcoma:

- Disease is advanced recurrent, metastatic, or inoperable, **and**
- Being used for inflammatory myofibroblastic tumor (IMT) with anaplastic lymphoma kinase (ALK) gene rearrangement, **and**
Being used as single agent therapy

Coverage Duration: one year

Effective Date: 8/30/2023